12:00 AM
May 13, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Samsca tolvaptan regulatory update

FDA issued a drug safety communication warning of a possible risk of liver injury in patients receiving Samsca tolvaptan from Otsuka to treat hypervolemic and euvolemic hyponatremia. FDA said the vasopressin 2 (V2) receptor antagonist should...

Read the full 169 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >